{"keywords": [{"value": "Pfizer Inc", "rank": "1", "is_major": "N", "name": "organizations"}, {"value": "Allergan Inc", "rank": "2", "is_major": "N", "name": "organizations"}, {"value": "Mergers, Acquisitions and Divestitures", "rank": "3", "is_major": "N", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "rank": "4", "is_major": "N", "name": "subject"}, {"value": "Federal Taxes (US)", "rank": "5", "is_major": "N", "name": "subject"}, {"value": "Corporate Taxes", "rank": "6", "is_major": "N", "name": "subject"}, {"value": "AstraZeneca PLC", "rank": "7", "is_major": "N", "name": "organizations"}, {"value": "GlaxoSmithKline PLC", "rank": "8", "is_major": "N", "name": "organizations"}, {"value": "Read, Ian C", "rank": "9", "is_major": "N", "name": "persons"}], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate"}, "byline": {"original": "By JOHN FOLEY", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "FOLEY", "firstname": "John"}]}, "web_url": "http://www.nytimes.com/2015/10/30/business/dealbook/pfizer-faces-challenges-in-pursuing-deal-for-a-lower-tax-rate.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "56324cbf38f0d8310a2a046f", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbWide.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbWide.jpg"}, {"height": 508, "subtype": "xlarge", "legacy": {"xlargeheight": "508", "xlargewidth": "600", "xlarge": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"}], "pub_date": "2015-10-30T00:00:00Z", "print_page": null, "section_name": "Business Day", "word_count": "401", "blog": [], "news_desk": "Business", "snippet": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.", "document_type": "article", "abstract": null, "lead_paragraph": "Allergan can hold out for a good price. But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal."}